Ypsomed Holding AG (XSWX:YPSN) EBIT: CHF244.2 Mil (TTM As of Mar. 2026)


XSWX:YPSN Ypsomed Holding AG XSWX:YPSN
91 GF Score
Price CHF353.00
GF Value CHF397.52
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Ypsomed Holding AG EBIT?

Ypsomed Holding AG XSWX:YPSN +1.91% 91 EBIT is CHF244.2 Mil as of Mar. 2026. GuruFocus rates XSWX:YPSN with a GF Score™ of 91/100 and a GF Value™ of CHF397.52 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Ypsomed Holding AG's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was CHF94.7 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was CHF244.2 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Ypsomed Holding AG's annualized ROC % for the quarter that ended in Mar. 2026 was 25.21%. Ypsomed Holding AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 22.96%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Ypsomed Holding AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 5.01%.


Ypsomed Holding AG  (XSWX:YPSN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Ypsomed Holding AG's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=337.94 * ( 1 - 11.61% )/( (1122.109 + 1247.62)/ 2 )
=298.705166/1184.8645
=25.21 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1208.679 - 50.269 - ( 36.301 - max(0, 251.676 - 369.986+36.301))
=1122.109

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1346.597 - 78.359 - ( 28.559 - max(0, 300.539 - 321.157+28.559))
=1247.62

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Ypsomed Holding AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=189.354/( ( (614.518 + max(71.65, 0)) + (827.738 + max(135.556, 0)) )/ 2 )
=189.354/( ( 686.168 + 963.294 )/ 2 )
=189.354/824.731
=22.96 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(142.067 + 69.394 + 111.865) - (50.269 + 0 + 201.407)
=71.65

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(186.924 + 60.608 + 39.563) - (78.359 + 0 + 73.18)
=135.556

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Ypsomed Holding AG's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=244.15/4873.084
=5.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ypsomed Holding AG EBIT Related Terms


Ypsomed Holding AG EBIT Historical Data

* Premium members only.

The historical data trend for Ypsomed Holding AG's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ypsomed Holding AG EBIT Chart

Ypsomed Holding AG Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.59 58.73 86.69 110.96 244.15

Ypsomed Holding AG Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.28 39.62 71.34 149.47 94.68

XSWX:YPSN vs ISRG, BDX, MDLN: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Ypsomed Holding AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ypsomed Holding AG EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Ypsomed Holding AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ypsomed Holding AG's EV-to-EBIT falls into.


XSWX:YPSN
91GF Score
Ypsomed Holding AG XSWX:YPSN
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ypsomed Holding AG EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF244.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of CHF244.2 Mil mean?
Ypsomed Holding AG (XSWX:YPSN) has a EBIT of CHF244.2 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Ypsomed Holding AG.
Is Ypsomed Holding AG's EBIT too high?
Ypsomed Holding AG's current EBIT is CHF244.2 Mil. Overall, Ypsomed Holding AG has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ypsomed Holding AG's EBIT compare to ISRG and BDX?
Ypsomed Holding AG's EBIT of CHF244.2 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Ypsomed Holding AG. Ypsomed Holding AG's current EBIT is CHF244.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ypsomed Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Ypsomed Holding AG (XSWX:YPSN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF397.52, compared to a current price of CHF353.00 — trading 11.2% below its estimated fair value. The current EBIT is CHF244.2 Mil. Ypsomed Holding AG's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Ypsomed Holding AG (XSWX:YPSN), the current EBIT is CHF244.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ypsomed Holding AG (XSWX:YPSN) Overvalued in 2026?

Based on GuruFocus' analysis, Ypsomed Holding AG stock appears to be undervalued. The current stock price of CHF353.00 is trading 11.2% below its estimated GF Value™ of CHF397.52. GuruFocus considers Ypsomed Holding AG to be Modestly Undervalued.

Key valuation signals for XSWX:YPSN:

  • EBIT: CHF244.2 Mil
  • GF Value™: CHF397.52 vs. price of CHF353.00 (11.2% below fair value)
  • GF Score™: 91/100 with 3 warning signs

No single metric tells the full story. See the XSWX:YPSN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ypsomed Holding AG Business Description

Other Exchanges YPSNz:UK0QLQ:UKOWX:Germany
Address Brunnmattstrasse 6, Burgdorf, CHE, 3401
Ypsomed Holding AG is a Swiss company that develops and manufactures injection and infusion systems that allow patients to self-administer medication. Specifically, the company focuses on ensuring the ease of diabetes and insulin injection. The company offers various products such as pen needles with a click-on function. The company operates under two reportable segments: Ypsomed Delivery Systems and Ypsomed Diabetes Care.
91GF Score

Get the complete analysis for XSWX:YPSN

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF353.00
Price
CHF397.52
GF Value